Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Dr. Falk Pharma GmbH
Sponsor

Dr. Falk Pharma GmbH

Germany Leinenweberstrasse 5, Hochdorf, 79108 Freiburg Im Breisgau, Germany

About the sponsor

Dr. Falk Pharma GmbH is active in eosinophilic esophagitis and in the prevention of oesophageal strictures after endoscopic treatment, with a clear focus on conditions affecting the oesophagus and swallowing function.

  • Eosinophilic esophagitis
  • Oesophageal stricture prevention
  • Budesonide orodispersible tablets

The sponsor also funds work on acute radiation proctitis, extending its interest in gastrointestinal inflammation beyond the upper digestive tract.

About Specializations

Dr. Falk Pharma GmbH runs clinical trials in conditions such as Cholangitis sclerosing, Coeliac disease, Proctitis, Impaired gastric emptying, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

7 clinical trials

Coeliac disease

Recruiting

Study on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Methyl (E,6S)-7-[[1-[2-(2-Ethylbutylamino)-2-Oxoethyl]-2-Oxopyridin-3-Yl]Amino]-6-[(3-Methylimidazole-4-Carbonyl)Amino]-7-Oxohept-2-Enoate
  • Sponsor:Dr. Falk Pharma GmbH

Proctitis

Recruiting

Study of budesonide suppositories to treat acute radiation proctitis in men with prostate cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Dr. Falk Pharma GmbH

Cholangitis sclerosing

Not recruiting

Study on the Safety and Tolerability of Norucholic Acid Tablets for Patients with Primary Sclerosing Cholangitis (PSC)

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Norucholic Acid
  • Sponsor:Dr. Falk Pharma GmbH

Impaired gastric emptying+1

Not recruiting

Study on the Safety and Effectiveness of Naronapride for Adults with Moderate Idiopathic or Diabetic Gastroparesis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Naronapride Dihydrochloride Trihydrate
  • Sponsor:Dr. Falk Pharma GmbH

Eosinophilic oesophagitis

Not recruiting

Study on Budesonide Tablets for Treating Eosinophilic Esophagitis in Adults

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Dr. Falk Pharma GmbH

Oesophageal squamous cell carcinoma+2

Not recruiting

Study on Budesonide Tablets for Preventing Esophageal Narrowing in Adults After Cancer Tissue Removal

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Dr. Falk Pharma GmbH

Cholangitis sclerosing

Not recruiting

Study on Norucholic Acid for Treating Primary Sclerosing Cholangitis in Patients

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Norucholic Acid
  • Sponsor:Dr. Falk Pharma GmbH

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.